Current progress in the development of RNAi-based therapeutics for HIV-1

Gene Therapy

Volumn 18, Issue 12, 2011, Pages 1134-1138

  Zhou, J ^a   Rossi, J J ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

delivery; HIV 1; RNAi; siRNA

Indexed keywords

APTAMER; CD34 ANTIGEN; CHEMOKINE RECEPTOR CCR5; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; VIRUS VECTOR;

CD4+ T LYMPHOCYTE; DRUG TARGETING; ENGRAFTMENT; GENE SEQUENCE; GENETIC TRANSCRIPTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LENTIVIRINAE; LIGAND BINDING; NONHUMAN; PRIORITY JOURNAL; REVIEW; RNA INTERFERENCE; RNA SEQUENCE; T LYMPHOCYTE; TREATMENT INDICATION; VIRAL GENE DELIVERY SYSTEM; VIRUS INHIBITION; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-HIV AGENTS; DRUG DELIVERY SYSTEMS; GENE THERAPY; HIV INFECTIONS; HIV-1; HUMANS; MOLECULAR TARGETED THERAPY; RNA, SMALL INTERFERING;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 83255187212     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2011.149     Document Type: Review

References (46)

1. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998; 391: 806-811. (Pubitemid 28099681)
2. Zamore PD. RNA interference: big applause for silencing in Stockholm. Cell 2006; 127: 1083-1086. (Pubitemid 44894537)
3. Castanotto D, Rossi JJ. The promises and pitfalls of RNA-interference- based therapeutics. Nature 2009; 457: 426-433.
4. Kim DH, Rossi JJ. Strategies for silencing human disease using RNA interference. Nat Rev Genet 2007; 8: 173-184.
5. De Fougerolles A, Vornlocher HP, Maraganore J, Lieberman J. Interfering with disease: a progress report on siRNA-based therapeutics. Nat Rev Drug Discov 2007; 6: 443-453. (Pubitemid 47064567)
6. Kurreck J. RNA interference: from basic research to therapeutic applications. Angew Chem Int Ed Engl 2009; 48: 1378-1398.
7. Zamore PD, Tuschl T, Sharp PA, Bartel DP. RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell 2000; 101: 25-33.
8. Song E, Lee SK, Wang J, Ince N, Ouyang N, Min J et al. RNA interference targeting Fas protects mice from fulminant hepatitis. Nat Med 2003; 9: 347-351. (Pubitemid 36362792)
9. Scherer L, Rossi JJ, Weinberg MS. Progress and prospects: RNA-based therapies for treatment of HIV infection. Gene Therapy 2007; 14: 1057-1064. (Pubitemid 47029489)
10. Singh SK, Gaur RK. Progress towards therapeutic application of RNA interference for HIV infection. BioDrugs 2009; 23: 269-276.
11. Haasnoot J, Westerhout EM, Berkhout B. RNA interference against viruses: strike and counterstrike. Nat Biotechnol 2007; 25: 1435-1443. (Pubitemid 350233142)
12. Boden D, Pusch O, Lee F, Tucker L, Ramratnam B. Human immunodeficiency virus type 1. escape from RNA interference. J Virol 2003; 77: 11531-11535. (Pubitemid 37271651)
13. Das AT, Brummelkamp TR, Westerhout EM, Vink M, Madiredjo M, Bernards R et al. Human immunodeficiency virus type 1 escapes from RNA interference-mediated inhibition. J Virol 2004; 78: 2601-2605. (Pubitemid 38228957)
14. Pusch O, Boden D, Silbermann R, Lee F, Tucker L, Ramratnam B. Nucleotide sequence homology requirements of HIV-1-specific short hairpin RNA. Nucleic Acids Res 2003; 31: 6444-6449. (Pubitemid 37508748)
15. Rossi JJ, June CH, Kohn DB. Genetic therapies against HIV. Nat Biotechnol 2007; 25: 1444-1454. (Pubitemid 350233141)
16. Richman DD, Margolis DM, Delaney M, Greene WC, Hazuda D, Pomerantz RJ. The challenge of finding a cure for HIV infection. Science 2009; 323: 1304-1307.
17. Tsygankov AY. Current developments in anti-HIV/AIDS gene therapy. Curr Opin Investig Drugs 2009; 10: 137-149.
18. Podlekareva D, Mocroft A, Dragsted UB, Ledergerber B, Beniowski M, Lazzarin A et al. Factors associated with the development of opportunistic infections in HIV-1-infected adults with high CD4f cell counts: a EuroSIDA study. J Infect Dis 2006; 194: 633-641. (Pubitemid 44297849)
19. Li MJ, Kim J, Li S, Zaia J, Yee JK, Anderson J et al. Long-term inhibition of HIV-1 infection in primary hematopoietic cells by lentiviral vector delivery of a triple combination of anti-HIV shRNA, anti-CCR5 ribozyme, and a nucleolar-localizing TAR decoy. Mol Ther 2005; 12: 900-909. (Pubitemid 41614486)
20. Brass AL, Dykxhoorn DM, Benita Y, Yan N, Engelman A, Xavier RJ et al. Identification of host proteins required for HIV infection through a functional genomic screen. Science 2008; 319: 921-926. (Pubitemid 351263756)
21. König R, Zhou Y, Elleder D, Diamond TL, Bonamy GM, Irelan JT et al. Global analysis of host-pathogen interactions that regulate early-stage HIV-1 replication. Cell 2008; 135: 49-60.
22. Zhou H, Xu M, Huang Q, Gates AT, Zhang XD, Castle JC et al. Genome-scale RNAi screen for host factors required for HIV replication. Cell Host Microbe 2008; 4: 495-504.
23. Goff SP. Knockdown screens to knockout HIV-1. Cell 2008; 135: 417-420.
24. ter Brake O, t Hooft K, Liu YP, Centlivre M, von Eije KJ, Berkhout B. Lentiviral vector design for multiple shRNA expression and durable HIV-1 inhibition. Mol Ther 2008; 16: 557-564. (Pubitemid 351314996)
25. Whitehead KA, Langer R, Anderson DG. Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov 2009; 8: 129-138.
26. Berkhout B, ter Brake O. Towards a durable RNAi gene therapy for HIV-AIDS. Expert Opin Biol Ther 2009; 9: 161-170.
27. Kumar P, Ban HS, Kim SS, Wu H, Pearson T, Greiner DL et al. T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice. Cell 2008; 134: 577-586.
28. Song E, Zhu P, Lee SK, Chowdhury D, Kussman S, Dykxhoorn DM et al. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol 2005; 23: 709-717. (Pubitemid 41716361)
29. Peipp M, Küpers H, Saul D, Schlierf B, Greil J, Zunino SJ et al. A recombinant CD7-specific single-chain immunotoxin is a potent inducer of apoptosis in acute leukemic T cells. Cancer Res 2002; 62: 2848-2855. (Pubitemid 34525770)
30. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, Hendrickson WA. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998; 393: 648-659. (Pubitemid 28289647)
31. Posner MR, Hideshima T, Cannon T, Mukherjee M, Mayer KH, Byrn RA. An IgG human monoclonal antibody that reacts with HIV-1/GP120, inhibits virus binding to cells, and neutralizes infection. J Immunol 1991; 146: 4325-4332.
32. Kim SS, Peer D, Kumar P, Subramanya S, Wu H, Asthana D et al. RNAi-mediated CCR5 silencing by LFA-1-targeted nanoparticles prevents HIV infection in BLT mice. Mol Ther 2010; 18: 370-376.
33. Neff CP, Zhou J, Remling L, Kuruvilla J, Zhang J, Li H et al. An aptamer-siRNA chimera suppresses HIV-1 viral loads and protects from helper CD4(r) T cell decline in humanized mice. Sci Transl Med 2011; 3: 66ra68.
34. Zhou J, Swiderski P, Li H, Zhang J, Neff CP, Akkina R et al. Selection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cells. Nucleic Acids Res 2009; 37: 3094-3109.
35. Zhou J, Li H, Li S, Zaia J, Rossi JJ. Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy. Mol Ther 2008; 16: 1481-1489.
36. Wheeler LA, Trifonova R, Vrbanac V, Basar E, McKernan S, Xu Z et al. Inhibition of HIV transmission in human cervicovaginal explants and humanized mice using CD4 aptamer-siRNA chimeras. J Clin Invest 2011; 121: 2401-2412.
37. Hussey RE, Richardson NE, Kowalski M, Brown NR, Chang HC, Siliciano RF et al. A soluble CD4 protein selectively inhibits HIV replication and syncytium formation. Nature 1988; 331: 78-81. (Pubitemid 18053421)
38. Sattentau QJ, Moore JP. The role of CD4 in HIV binding and entry. Philos Trans R Soc Lond B Biol Sci 1993; 342: 59-66.
39. Dalgleish AG, Beverley PC, Clapham PR, Crawford DH, Greaves MF, Weiss RA. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature 1984; 312: 763-767. (Pubitemid 15195924)
40. Kraus E, James W, Barclay AN. Cutting edge: novel RNA ligands able to bind CD4 antigen and inhibit CD4f T lymphocyte function. J Immunol 1998; 160: 5209-5212. (Pubitemid 28267804)
41. Hütter G, Nowak D, Mossner M, Ganepola S, Müssig A, Allers K et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med 2009; 360: 692-698.
42. Robbins MA, Li M, Leung I, Li H, Boyer DV, Song Y et al. Stable expression of shRNAs in human CD34f progenitor cells can avoid induction of interferon responses to siRNAs in vitro. Nat Biotechnol 2006; 24: 566-571.
43. DiGiusto DL, Krishnan A, Li L, Li H, Li S, Rao A et al. RNA-based gene therapy for HIV with lentiviral vector-modified CD34(r) cells in patients undergoing transplantation for AIDS-related lymphoma. Sci Transl Med 2010; 2: 36ra43.
44. Berkhout B. Toward a durable anti-HIV gene therapy based on RNA interference. Ann NY Acad Sci 2009; 1175: 3-14.
45. Berkhout B, Sanders RW. Molecular strategies to design an escape-proof antiviral therapy. Antiviral Res 2011; 92: 7-14.
46. Liu YP, Berkhout B. Lentiviral delivery of RNAi effectors against HIV-1. Curr Top Med Chem 2009; 9: 1130-1143.